Bioengineered Vascular Grafts: Advances, Clinical Applications, and Future Directions

Abstract

Bioengineered vascular grafts represent a remarkable innovation in the field of vascular surgery, offering novel solutions for patients with vascular disease who require arterial or venous replacement but lack suitable autologous conduits. This review synthesizes current evidence on the development, mechanisms, clinical outcomes, and future prospects of bioengineered vascular grafts, emphasizing their relevance for contemporary vascular practice. Key areas include epidemiology of vascular disease, underlying pathophysiology, patient risk profiles, clinical presentation, diagnostic approaches, established and emerging therapies, and evidence-based guideline recommendations.

Introduction

Vascular grafting is foundational in the management of arterial occlusive disease, aneurysms, trauma, and hemodialysis access. While autologous vessels remain the gold standard for many applications, limitations in availability and suitability necessitate alternative approaches. The evolution of bioengineered vascular grafts—engineered by combining scaffold materials with cellular or acellular components—has been propelled by advances in biomaterials science, tissue engineering, and regenerative medicine. This article provides a comprehensive overview of bioengineered vascular grafts, underscoring their clinical significance and future potential in vascular surgery.

Epidemiology / Disease Burden

Cardiovascular disease, particularly atherosclerosis, is the leading cause of morbidity and mortality worldwide. The global burden of peripheral arterial disease (PAD) affects over 200 million individuals. Aortic aneurysms, critical limb ischemia, and vascular trauma contribute additional demand for vascular reconstruction. Despite improvements in medical management, surgical revascularization remains essential for limb salvage and survival in advanced disease. However, up to 30% of patients lack suitable autologous veins for bypass, highlighting the need for effective alternatives such as bioengineered grafts.

Pathophysiology

Native vessel failure in vascular disease is primarily driven by atherosclerosis, thrombosis, and degenerative changes. Synthetic grafts, while available, often succumb to neointimal hyperplasia, thrombosis, or infection, especially in small-diameter applications (<6 mm). Bioengineered vascular grafts are designed to mimic the mechanical and biological properties of native vessels, supporting endothelialization, inhibiting thrombosis, and enabling remodeling—thus addressing the limitations of existing synthetic options.

Risk Factors

Traditional cardiovascular risk factors—hypertension, diabetes mellitus, dyslipidemia, smoking, and advanced age—predispose to vascular disease and may also impact graft patency and healing. Additional challenges include hypercoagulable states, infection risk, and poor target vessel quality. The immunogenicity of graft materials and patient-specific inflammatory responses are critical considerations in evaluating graft performance and long-term outcomes.

Clinical Features

Patients requiring vascular grafts typically present with features of arterial insufficiency (claudication, rest pain, tissue loss), aneurysmal disease (pulsatile mass, rupture), or vascular trauma (ischemia, hemorrhage). In dialysis-dependent individuals, vascular access failure manifests as inadequate flow or thrombosis. The clinical scenario dictates graft selection, with bioengineered options considered when autologous vessels are unavailable or unsuitable.

Diagnosis

Diagnosis involves a combination of clinical assessment and imaging modalities such as duplex ultrasonography, computed tomography angiography (CTA), and magnetic resonance angiography (MRA). These tools delineate vascular anatomy, identify occlusions or aneurysms, and inform graft planning. Preoperative evaluation also includes assessment of potential conduit availability and suitability, further supporting the rationale for bioengineered grafts in selected cases.

Treatment & Management

Conventional vascular grafts include autologous veins (e.g., great saphenous vein), synthetic materials (expanded polytetrafluoroethylene [ePTFE], Dacron), and cryopreserved allografts. Bioengineered vascular grafts are developed using decellularized scaffolds, polymeric materials, and seeding with autologous or allogeneic cells to promote integration and function. Clinical management involves careful patient selection, perioperative antithrombotic therapy, and surveillance for complications such as graft thrombosis, infection, and anastomotic failure.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in the field of bioengineered vascular grafts. Notable technologies include tissue-engineered blood vessels (TEBVs) constructed from decellularized human or animal matrices, self-assembling scaffolds, and bioprinted vascular conduits. Several early-phase clinical trials, such as those investigating the Humacyte human acellular vessel, have demonstrated promising patency rates, resistance to infection, and remodeling capacity in both arterial and hemodialysis access settings. Ongoing research aims to optimize cellularization, enhance mechanical strength, and enable off-the-shelf availability with minimal immunogenicity.

Guideline Recommendations

Major vascular surgery and cardiovascular guidelines continue to endorse autologous conduits as the first-line choice for most peripheral and coronary bypass procedures. Synthetic grafts are recommended when autologous options are not available, with recognition of their limitations in small-diameter applications. Emerging guidelines increasingly acknowledge the role of bioengineered vascular grafts, particularly in complex reconstructions, reoperative fields, and high-risk patients. Participation in clinical trials and adherence to rigorous follow-up are advised when using novel graft technologies.

Conclusion

Bioengineered vascular grafts offer transformative potential for vascular reconstruction, addressing unmet needs in patients lacking suitable autologous conduits. With ongoing advances in biomaterials, tissue engineering, and cellular therapies, these grafts are poised to redefine standards of care in vascular surgery. Continued research, clinical trials, and long-term outcome studies are essential to establish their safety, efficacy, and optimal applications. For clinicians, understanding the scientific basis and practical considerations of bioengineered vascular grafts is crucial in delivering evidence-based, patient-centered vascular care.